Evidence map›Paper›PMID 34823323›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2022

Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma

Ahmet Şeyhanlı, Boran Yavuz, Zehra Akşit, Zeynep Yüce, Sermin Özkal, Oğuz Altungöz, Fatih Demirkan, İnci Alacacıoğlu, Güner Hayri Özsan

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ahmet ŞeyhanlıSivas Numune Hospital, Clinic of Hematology, Sivas, TurkeyORCID 0000-0001-6082-2995
Boran YavuzDokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, TurkeyORCID 0000-0002-3799-0461
Zehra AkşitDokuz Eylül University Faculty of Medicine, Department of Internal Medicine, İzmir, TurkeyORCID 0000-0003-3638-4491
Zeynep YüceDokuz Eylül University Faculty of Medicine, Department of Medical Biology, İzmir, Turkey
Sermin ÖzkalDokuz Eylül University Faculty of Medicine, Department of Pathology, İzmir, TurkeyORCID 0000-0002-8167-0238
Oğuz AltungözDokuz Eylül University Faculty of Medicine, Department of Medical Biology, İzmir, TurkeyORCID 0000-0002-2548-4238
Fatih DemirkanDokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, TurkeyORCID 0000-0002-1172-8668
İnci AlacacıoğluDokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, TurkeyORCID 0000-0002-8187-7159
Güner Hayri ÖzsanDokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, TurkeyORCID 0000-0002-0930-6300
Dokuz Eylül University · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Multiple myeloma (MM) is a malignant condition characterized by the accumulation of malignant plasma cells. Although MM remains incurable, the survival of MM patients has improved considerably due to the application of autologous stem cell transplantation, novel agents, and advanced treatment strategies. This study aimed to determine the cytogenetic characterization and bone marrow (BM) features of Turkish patients with MM. Materials and Methods: Eighty-five MM patients were admitted to Dokuz Eylül University Hospital in Turkey. BM samples of these MM patients were subjected to cytogenetic analyses at diagnosis and during therapy as a part of therapeutical and clinical evaluation. A complete cytogenetic study was performed using the G-banding technique. Fluorescence in situ hybridization (FISH) analysis was performed using cytoplasmic immunoglobulin. The degree of BM fibrosis was determined using reticulin histochemical staining. We determined the percentage of BM plasma cells based on the extent of CD38 staining. Results: Eighty-five MM patients were retrospectively identified between 2015 and 2021. The median age was 63 (38-90) years. Of the 85 patients, 60 (70.6%) were male and 25 (29.4%) were female. Seventy-two (84.7%) cases had BM fibrosis at the time of diagnosis. The most common was grade 2 fibrosis, recorded in 35 cases (41.2%). About 72.9% of the patients showed more than 50% plasma cells. FISH analysis indicated the presence of abnormal chromosomes in 37% (32/85) of the patients. The most frequent abnormality was Immunoglobulin heavy-chain (IGH) translocation (21.3%). Conclusion: Subgroup analysis of IGH mutations is crucial in the identification of high-risk MM patients. We believe that our study will contribute to the determination of BM biopsy and cytogenetic features of MM patients in our country.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAdultAgedAged, 80 and overBiopsyBone MarrowCytogenetic AnalysisFemaleFibrosisHumansImmunoglobulinsIn Situ Hybridization, FluorescenceMaleMiddle AgedRetrospective StudiesImmunoglobulinsBone marrow biopsyCytogeneticanalysisFluorescence in situ hybridizationMultiple myeloma

Identifiers

PMID34823323
PMCPMC9160703
OpenAlexW3217747613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.